ECM31 Antibody

What are the primary applications for CD31/PECAM-1 antibodies in research?

CD31/PECAM-1 antibodies are versatile tools employed across multiple experimental techniques:

• Western Blotting: Detects CD31/PECAM-1 protein (approximately 130 kDa) in cell lysates such as HUVEC human umbilical vein endothelial cells

• Immunohistochemistry (IHC): Visualizes CD31/PECAM-1 expression in paraffin-embedded or frozen tissue sections, particularly in blood vessels and endothelial cells

• Immunofluorescence (IF): Identifies CD31/PECAM-1 localization in fixed cells or tissues with fluorescent detection systems

• Immunoprecipitation (IP): Isolates CD31/PECAM-1 and its binding partners from complex protein mixtures

The optimal dilution ranges vary by application, typically 1:50-1:100 for immunocytochemistry/immunofluorescence and 1:1000 for Western blotting .

What cell types and tissues are most appropriate for CD31/PECAM-1 antibody studies?

CD31/PECAM-1 antibodies primarily target:

• HUVECs (Human Umbilical Vein Endothelial Cells): The gold standard model for CD31/PECAM-1 expression studies

• Arterial Tissue: CD31/PECAM-1 antibodies effectively label endothelial cells lining blood vessels in human arteries

• THP-1 Cells: Human monocytic cell line that expresses CD31/PECAM-1 (with knockout controls available)

• Various Human Tissues: Including liver vasculature and muscle tissue, where CD31 marks endothelial cells

What are the essential antigen retrieval methods for CD31/PECAM-1 detection in IHC?

For optimal CD31/PECAM-1 detection in fixed tissues:

• Paraffin-embedded tissues: Heat-induced epitope retrieval using basic pH buffers (such as VisUCyte Antigen Retrieval Reagent-Basic) is recommended before immunostaining

• Frozen sections: Permeabilization with 80% acetone enhances antibody accessibility to the antigen

• Citrate buffer method: 10mM Citrate pH6 has been validated for muscle tissue sections

Primary antibody incubation typically occurs overnight at 4°C at dilutions of 1:100-1:800 depending on the antibody clone and tissue type .

How can researchers validate CD31/PECAM-1 antibody specificity in their experimental systems?

Rigorous validation strategies include:

• Knockout controls: Compare staining between wild-type and CD31/PECAM-1 knockout cell lines (e.g., THP-1 cells and CD31/PECAM-1 knockout THP-1 cells)

• Multiple detection methods: Confirm findings using orthogonal techniques such as Western blot, IF, and IHC on the same sample type

• Expected subcellular localization: Verify that staining patterns align with known membrane localization of CD31/PECAM-1

• Molecular weight verification: Confirm detection of a ~130 kDa band in Western blot under reducing conditions

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to demonstrate binding specificity

What are the critical considerations when using CD31/PECAM-1 antibodies in co-localization studies with ECM proteins?

When investigating CD31/PECAM-1 interaction with extracellular matrix (ECM) components:

• Sample preparation: Different fixation methods may differentially preserve CD31/PECAM-1 epitopes versus ECM protein structures; cross-linking fixatives like paraformaldehyde maintain structural relationships better than precipitating fixatives

• Antibody compatibility: Select CD31/PECAM-1 antibodies raised in different host species from your ECM antibodies to avoid cross-reactivity in double-labeling experiments

• Sequential immunostaining: For challenging co-localization studies, perform sequential rather than simultaneous immunolabeling, with complete blocking steps between antibody applications

• Control for specificity: Include appropriate blocking of adhesion domains, as antibodies specific for both functional domains will be required to effectively interfere with adhesion to ECM components

How should researchers interpret contradictory CD31/PECAM-1 staining patterns between different antibody clones?

When facing discrepancies between experiments:

• Epitope differences: Different antibody clones (e.g., 9G11 vs. 89C2) recognize distinct epitopes on CD31/PECAM-1 that may be differentially accessible depending on protein conformation or complexation with binding partners

• Fixation-sensitive epitopes: Some epitopes are denatured or masked by certain fixation protocols; test multiple fixation methods if unexpected results occur

• Glycosylation variability: CD31/PECAM-1 is heavily glycosylated, which can interfere with antibody binding in certain contexts or tissues

• Protein-protein interactions: CD31/PECAM-1 binding to other proteins like fibronectin (Fn) can induce conformational changes that expose or hide certain epitopes, similar to ligand-induced binding sites (LIBS) described for other adhesion molecules

What methodological approaches can optimize CD31/PECAM-1 antibody performance in challenging tissue samples?

For difficult-to-stain samples:

• Signal amplification: Employ tyramide signal amplification or polymer-based detection systems like Anti-Mouse IgG VisUCyte HRP Polymer Antibody for improved sensitivity in tissues with low CD31 expression

• Extended primary antibody incubation: Increase incubation time to overnight at 4°C rather than 1 hour at room temperature for better penetration in dense tissues

• Dual fluorophore validation: Use multiple secondary antibodies with different fluorophores to confirm specific binding versus autofluorescence in highly vascularized tissues

• Titration optimization: Systematically test dilution series (1:50, 1:100, 1:200, etc.) for each new tissue type to determine optimal signal-to-noise ratio

How can CD31/PECAM-1 antibodies be effectively used to quantify angiogenesis in experimental models?

For angiogenesis quantification:

• Vessel density analysis: Count CD31-positive vessels per high-power field across multiple fields (minimum 5-10) to obtain reliable measures of vascularization

• Morphometric analysis: Beyond simple counting, measure vessel diameter, branching points, and total vessel area using CD31 staining and image analysis software

• Co-staining strategies: Combine CD31 with proliferation markers (Ki-67) to specifically identify newly formed vessels versus pre-existing vasculature

• Control selection: Include both positive controls (known vascular tissues) and negative controls (CD31-negative tissues) in each experiment to validate staining protocols

What are the critical differences between monoclonal and polyclonal CD31/PECAM-1 antibodies for specific research applications?

Choosing between antibody types:

• Monoclonal advantages: Clones like 9G11 and 89C2 offer high specificity for particular epitopes, batch-to-batch consistency, and reduced background, making them ideal for quantitative studies

• Polyclonal benefits: Recognition of multiple epitopes potentially increases detection sensitivity in partially denatured samples and may better tolerate fixation-induced conformational changes

• Application considerations: Monoclonals may be preferred for Western blotting and quantitative IF work, while polyclonals might offer advantages in certain IHC applications on fixed tissues

• Epitope accessibility: Some monoclonal antibodies like 9C3 recognize highly specific epitopes (e.g., SVDFEED sequence) that may be masked in certain experimental conditions

How should researchers address non-specific background when using CD31/PECAM-1 antibodies in highly vascularized tissues?

Background reduction strategies:

• Extended blocking: Increase blocking time (2-3 hours) with serum matching the host species of the secondary antibody plus 1% BSA to reduce non-specific binding

• Endogenous peroxidase quenching: For IHC with HRP detection systems, thorough quenching of endogenous peroxidase activity with H₂O₂ treatment is essential

• Endogenous biotin blocking: When using biotin-streptavidin detection systems, block endogenous biotin with avidin-biotin blocking kits

• Secondary antibody optimization: Use highly cross-adsorbed secondary antibodies to minimize cross-reactivity with endogenous immunoglobulins in tissue samples

• Titration of primary antibody: Determine the minimum concentration of CD31 antibody needed for specific signal detection (typically between 1:800-1:3200 for immunohistochemistry)

How can CD31/PECAM-1 antibody staining patterns differentiate between various endothelial cell subtypes?

Endothelial heterogeneity analysis:

• Staining intensity: Arterial endothelial cells typically exhibit stronger CD31 membrane staining than venous endothelial cells

• Morphological correlation: Combine CD31 staining with morphological assessment to distinguish capillary (flat, elongated) from arterial or venous (more cuboidal) endothelial cells

• Co-marker analysis: Pair CD31 with EphB4 (venous marker) or ephrinB2 (arterial marker) to definitively identify vessel subtypes

• Quantitative thresholding: Apply consistent intensity thresholds across samples when performing quantitative image analysis of different vascular beds

What strategies can enhance CD31/PECAM-1 detection in multiplex immunofluorescence panels?

Multiplex optimization approaches:

• Sequential antibody application: Apply antibodies sequentially rather than in a cocktail to minimize steric hindrance between adjacent epitopes

• Spectral separation: Select fluorophores with minimal spectral overlap; NorthernLights 557 (red) works well with DAPI (blue) for CD31 co-staining

• Hierarchy of detection: Apply the CD31 antibody first in multiplex panels, as it targets an abundant antigen with robust expression compared to many other markers

• Panel validation: Thoroughly validate each antibody individually before combining them in multiplex panels to ensure no interference occurs

How should researchers interpret CD31/PECAM-1 expression in non-endothelial cell populations?

Non-endothelial CD31 interpretation:

• Leukocyte expression: CD31 expression on leukocytes like THP-1 cells is typically lower than on endothelial cells and may require more sensitive detection methods

• Expression quantification: Use quantitative methods (flow cytometry, Western blotting with calibration standards) to compare expression levels between different cell types

• Validation controls: Include known positive (HUVEC) and negative control cell types, as well as isotype controls, to establish detection thresholds

• Functional context: Consider the functional significance of CD31 in different cell types - adhesive functions in endothelial cells versus potential signaling roles in leukocytes

How can synthetic peptide approaches improve antibody development against functional domains of adhesion molecules like CD31/PECAM-1?

Advanced antibody development:

• Synthetic peptide immunogens: Using short synthetic peptides (e.g., 14-18 amino acids) that contain conserved functional domains but are unable to bind their ligands can effectively stimulate production of antibodies against essential epitopes

• Epitope targeting: Antibodies developed against specific linear epitopes within conserved patterns (like the SVDFEED sequence) can effectively block protein-protein interactions

• Combined antibody strategies: Mixing antibodies targeting different functional domains (e.g., anti-D1 and anti-D3) can achieve greater inhibition of binding interactions than either antibody alone

• LIBS avoidance: Synthetic peptide approaches help avoid generating antibodies against ligand-induced binding sites (LIBS), which can occur during natural infections and might actually stimulate rather than inhibit binding interactions

What are the critical considerations when using CD31/PECAM-1 antibodies in the characterization of stem cell-derived endothelial cells?

Stem cell research applications:

• Temporal expression analysis: Monitor CD31 expression throughout differentiation timeline to track endothelial commitment of stem cells

• Functional correlation: Correlate CD31 expression with other endothelial markers (vWF, isolectin-B4 binding) to confirm complete functional differentiation

• Quantification methods: Determine percentage of CD31-positive cells among total DAPI-positive populations to assess differentiation efficiency

• Comparison to native endothelium: Always include mature endothelial cells (HUVECs) as positive controls when characterizing stem cell-derived populations